This experiment aims to validate a multimodal biomarker panel for early diagnosis, disease progression monitoring, and therapeutic response prediction in Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Currently, there are no validated biomarkers for these 4R-tauopathies, making differential diagnosis challenging and clinical trial enrollment inefficient.
Primary Hypothesis: A combination of fluid biomarkers (NfL, p-tau181, p-tau217), imaging biomarkers (tau PET, MRI atrophy patterns), and genetic markers will achieve ≥90% sensitivity and specificity for distinguishing PSP/CBS from other neurodegenerative diseases.
Secondary Hypothesis: Baseline biomarker levels will predict disease progression rate and treatment response in clinical trials.
Current challenges in PSP/CBS diagnosis and monitoring:
- Clinical diagnosis relies on symptom presence, often delaying accurate diagnosis by 2-3 years
- No validated biomarkers for differential diagnosis
- Clinical trial endpoints are insensitive to early disease changes
- Patient stratification for clinical trials is suboptimal
Existing biomarker candidates:
- Type: Prospective, multi-center, longitudinal cohort
- Duration: 36 months
- Sample Size: 300 participants
- PSP (n=120, Richardson syndrome and variants)
- CBS (n=80)
- Parkinson's disease (n=50, disease control)
- Healthy controls (n=50)
- Age 50-80 years
- Possible or probable PSP (MDS-PSP criteria) or CBS (Cambridge criteria)
- MMSE ≥ 20
- Ability to undergo MRI and lumbar puncture
- Plasma and CSF NfL (Simoa)
- Plasma and CSF p-tau181, p-tau217 (Lumipulse)
- Plasma and CSF total tau
- Neurogranin (synaptic marker)
- Alpha-synuclein seeding assay
- 4R-tau specific assays (developing)
- MRI: 3D T1, T2/FLAIR, DTI
- Volumetry: midbrain, pons, SCP, basal ganglia
- Diffusion: white matter tract integrity
- Tau PET: 4R-selective tracer (PI-2620 or successor)
- Regional SUVR binding
- Kinetic modeling
- MAPT H1/H2 haplotype
- Known PSP/CBS risk variants (C9orf72, etc.)
- Polygenic risk score
- PSP Rating Scale (PSPRS)
- MDS-UPDRS
- Mini-Mental State Examination
- Frontal Assessment Battery
- Montreal Cognitive Assessment
- Quality of life measures (PSP-QoL, PDQ-39)
¶ Reagents and Equipment
| Item |
Supplier |
Cost (USD) |
| NfL Simoa assay kit |
Quanterix |
$85,000 |
| p-tau181/217 Lumipulse kits |
Fujirebio |
$120,000 |
| Tau PET tracer (PI-2620) |
Avid/Gray Matter |
$250,000 |
| MRI scanning (per session) |
Multi-site |
$300,000 |
| CSF collection supplies |
Qiagen/Sarstedt |
$15,000 |
| Genetic sequencing |
Illumina |
$40,000 |
| Bioinformatics infrastructure |
In-house |
$50,000 |
| Clinical coordination |
Multi-site |
$150,000 |
Estimated Total Cost: $1,010,000
- University College London — Prof. Huw Morris's group (PSP biomarkers)
- University of Pennsylvania — Dr. John Trojanowski's group (fluid biomarkers)
- Banner Sun Health — Dr. Thomas Beach's group (neuropathology validation)
- MassGeneral Hospital — Dr. Bradley Hutton's group (tau PET)
- University of Tübingen — Prof. Klaus Fassbender's group (clinical trials)
- Months 1-6: Protocol finalization, site preparation, assay validation
- Months 7-30: Participant recruitment and follow-up
- Months 31-36: Data analysis, biomarker panel development, publication
Total Duration: 36 months
- Develop validated biomarker panel achieving ≥90% sensitivity/specificity for PSP vs PD
- Establish baseline biomarker thresholds predicting rapid progression
- Identify biomarkers correlating with therapeutic response
- Characterize biomarker trajectories over disease progression
- Validate imaging biomarkers against neuropathology (autopsy cases)
- Create clinically implementable biomarker algorithm
- Blood-based screening test (NfL + p-tau)
- Confirmatory MRI protocol
- Optional tau PET for clinical trial enrichment
| Dimension |
Score (1-10) |
Rationale |
| Scientific Value |
10 |
Addresses critical gap in PSP/CBS biomarker field |
| Feasibility |
8 |
Leverages existing assays and imaging protocols |
| Novelty |
9 |
First comprehensive multimodal biomarker validation |
| Disease Impact |
10 |
Enables earlier diagnosis and better clinical trials |
| Reach |
9 |
Benefits all PSP/CBS patients (60K US, 120K EU) |
| Cost Efficiency |
7 |
High cost but addresses multiple needs |
| Time Efficiency |
7 |
36 months reasonable for longitudinal study |
| Evidence Base |
8 |
Strong preliminary data for candidate biomarkers |
| Addresses Uncertainty |
10 |
Tests critical diagnostic and prognostic questions |
| Translation Potential |
10 |
Clear path to clinical implementation |
Total Score: 88 × weight normalization = ~125/140